{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:04:12Z","timestamp":1790885052726,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11926-024-01143-y","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T03:27:30Z","timestamp":1712287650000},"page":"260-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Decoding the Intricacies of Statin-Associated Muscle Symptoms"],"prefix":"10.1007","volume":"26","author":[{"given":"Tara Fallah","family":"Rastegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiaz Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"1143_CR1","unstructured":"Cardiovascular diseases (CVDs) [Internet]. [cited 2023 Oct 12]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"issue":"5519","key":"1143_CR2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160\u20134.","journal-title":"Science"},{"key":"1143_CR3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","volume":"328","author":"JE Blais","year":"2021","unstructured":"Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44\u201351.","journal-title":"Atherosclerosis"},{"issue":"9","key":"1143_CR4","doi-asserted-by":"crossref","first-page":"e061350","DOI":"10.1136\/bmjopen-2022-061350","volume":"12","author":"JS Guadamuz","year":"2022","unstructured":"Guadamuz JS, Shooshtari A, Qato DM. Global, regional and national trends in statin utilisation in high-income and low\/middle-income countries, 2015\u20132020. BMJ Open. 2022;12(9):e061350.","journal-title":"BMJ Open"},{"issue":"3 Suppl","key":"1143_CR5","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association\u2019s Muscle Safety Expert Panel null. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58-71.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1143_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/01.bor.0000434673.85515.89","volume":"25","author":"P Mohassel","year":"2013","unstructured":"Mohassel P, Mammen AL. The spectrum of statin myopathy. Curr Opin Rheumatol. 2013;25(6):747\u201352.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1143_CR7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/jcm9010022","volume":"9","author":"RM Turner","year":"2019","unstructured":"Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9(1):22.","journal-title":"J Clin Med"},{"key":"1143_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.phrs.2014.04.012","volume":"88","author":"GD Norata","year":"2014","unstructured":"Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol Res. 2014;88:107\u201313.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1143_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/17425255.2020.1802426","volume":"16","author":"JJ Li","year":"2020","unstructured":"Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. Expert Opin Drug Metab Toxicol. 2020;16(9):837\u201351.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"1143_CR10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcrc.2010.04.002","volume":"25","author":"S Kasaoka","year":"2010","unstructured":"Kasaoka S, Todani M, Kaneko T, Kawamura Y, Oda Y, Tsuruta R, et al. Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care. 2010;25(4):601\u20134.","journal-title":"J Crit Care"},{"issue":"9","key":"1143_CR11","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200 and 100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757\u201366 This study defined the first description of the anti-HMGCR autoantibody.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1143_CR12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321.","journal-title":"Arthritis Rheum"},{"issue":"3 Suppl","key":"1143_CR13","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","volume":"8","author":"JR Guyton","year":"2014","unstructured":"Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel null. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72-81.","journal-title":"J Clin Lipidol."},{"issue":"5","key":"1143_CR14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472\u201383.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1143_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11(1):1\u201323.","journal-title":"Arch Med Sci"},{"issue":"7 Suppl","key":"1143_CR16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","volume":"32","author":"GBJ Mancini","year":"2016","unstructured":"Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32(7 Suppl):S35-65.","journal-title":"Can J Cardiol"},{"issue":"2","key":"1143_CR17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/03007995.2016.1252740","volume":"33","author":"AC Sposito","year":"2017","unstructured":"Sposito AC, Faria Neto JR, de Carvalho LSF, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33(2):239\u201351.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1143_CR18","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/gerona\/62.8.879","volume":"62","author":"CGP Roberts","year":"2007","unstructured":"Roberts CGP, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2007;62(8):879\u201387.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"1143_CR19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833\u201341.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"1143_CR20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacl.2016.05.003","volume":"10","author":"EA Brinton","year":"2016","unstructured":"Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. J Clin Lipidol. 2016;10(4):1022\u20139.","journal-title":"J Clin Lipidol"},{"issue":"178","key":"1143_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","volume":"15","author":"M Michalska-Kasiczak","year":"2015","unstructured":"Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;15(178):111\u20136.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1143_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","volume":"8","author":"CD Robison","year":"2014","unstructured":"Robison CD, Bair TL, Horne BD, McCubrey RO, Lappe DL, Muhlestein JB, et al. Hypothyroidism as a risk factor for statin intolerance. J Clin Lipidol. 2014;8(4):401\u20137.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"1143_CR23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858\u201368.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1143_CR24","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1093\/rheumatology\/keac198","volume":"61","author":"M Muruganandam","year":"2022","unstructured":"Muruganandam M, Iqbal A, Akpan EB, Dolomisiewicz AC, Waters YM, Emil NS, et al. Statin-associated immune-mediated necrotizing myositis in Native Americans. Rheumatology (Oxford). 2022;61(12):4855\u201362 This study is one of several publications highlighting the increased risk of autoimmune statin myopathy in Native American patients.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1143_CR25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/keaa337","volume":"60","author":"RM Close","year":"2021","unstructured":"Close RM, Close LM, Galdun P, Gerstberger S, Rydberg M, Christopher-Stine L. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology (Oxford). 2021;60(2):692\u20138 This study is the first report in the medical literature about the potential increased risk of anti-HMGCR myopathy in Native Americans with elevated lipids.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1143_CR26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/phar.2674","volume":"42","author":"NC Schwier","year":"2022","unstructured":"Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug-drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022;42(4):320\u201333.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"1143_CR27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","volume":"17","author":"T Stulc","year":"2015","unstructured":"Stulc T, Ce\u0161ka R, Gotto AM. Statin intolerance: the clinician\u2019s perspective. Curr Atheroscler Rep. 2015;17(12):69.","journal-title":"Curr Atheroscler Rep"},{"key":"1143_CR28","unstructured":"Nidhaan A, Hastings A, Gonzalez D, Joshi R, Gilbert N, O\u2019connor C. Frequency of checking creatine kinase in patients on statins with elevated transaminase for early detection of statin induced myopathy [abstract]. Arthritis Rheumatol. 2022;74 (suppl 9). https:\/\/acrabstracts.org\/abstract\/frequency-of-checking-creatine-kinase-in-patients-on-statins-with-elevated-transaminase-for-early-detection-of-statin-induced-myopathy\/. Accessed\u00a0Nov 8, 2023"},{"issue":"2","key":"1143_CR29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179\u201386.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"21","key":"1143_CR30","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.3390\/ijms222111687","volume":"22","author":"P Vinci","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):11687.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1143_CR31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","volume":"14","author":"A Selva-O\u2019Callaghan","year":"2018","unstructured":"Selva-O\u2019Callaghan A, Alvarado-Cardenas M, Pinal-Fern\u00e1ndez I, Trallero-Aragu\u00e1s E, Milisenda JC, Mart\u00ednez M\u00c1, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):215\u201324.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"1143_CR32","doi-asserted-by":"crossref","first-page":"e2217831120","DOI":"10.1073\/pnas.2217831120","volume":"120","author":"Y Yogev","year":"2023","unstructured":"Yogev Y, Shorer Z, Koifman A, Wormser O, Drabkin M, Halperin D, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci. 2023;120(7):e2217831120 This study shows that mevalonolactone can protect mice from myotoxicity induced by high-dose statin. This could be applicable in some anti-HMGCR autoantibody positive patients.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"1143_CR33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcsm.12654","volume":"12","author":"H Mollazadeh","year":"2021","unstructured":"Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2):237\u201351.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"1143_CR34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00228-020-03019-3","volume":"77","author":"M Liu","year":"2021","unstructured":"Liu M, Fan F, Zhang Y, Li J. The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2021;77(3):349\u201357.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1143_CR35","first-page":"13","volume":"14","author":"JT Davies","year":"2016","unstructured":"Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;14(9):13\u201329.","journal-title":"Lipid Insights"},{"issue":"6","key":"1143_CR36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41397-018-0054-0","volume":"18","author":"Q Xiang","year":"2018","unstructured":"Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J. 2018;18(6):721\u20139.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"1143_CR37","first-page":"328","volume":"22","author":"R Balasubramanian","year":"2021","unstructured":"Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab. 2021;22(5):328\u201341.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"1143_CR38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1574884715666200827105612","volume":"16","author":"ZM Shahrure","year":"2021","unstructured":"Shahrure ZM, Irshaid YM, Mustafa KN, Abujbara MA, Al Shhab M, El-Khateeb MS, et al. SLCO1B1 gene polymorphisms (rs2306283 and rs4149056) and statin-induced myopathy in Jordanian diabetics. Curr Rev Clin Exp Pharmacol. 2021;16(3):281\u20138.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"4","key":"1143_CR39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00228-020-03029-1","volume":"77","author":"Q Xiang","year":"2021","unstructured":"Xiang Q, Zhang XD, Mu GY, Wang Z, Liu ZY, Xie QF, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77(4):569\u201381.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1143_CR40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41397-021-00208-w","volume":"21","author":"S Turongkaravee","year":"2021","unstructured":"Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021;21(3):296\u2013307.","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"1143_CR41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","volume":"20","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21.","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"1143_CR42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1586\/1744666X.2015.1102632","volume":"11","author":"A Selva-O\u2019Callaghan","year":"2015","unstructured":"Selva-O\u2019Callaghan A, Alvarado-Cardenas M, Marin A, Pinal-Fernandez I. Statins and myositis: the role of anti-HMGCR antibodies. Expert Rev Clin Immunol. 2015;11(12):1277\u20139.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1143_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","volume":"52","author":"T Chung","year":"2015","unstructured":"Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve. 2015;52(2):189\u201395.","journal-title":"Muscle Nerve"},{"issue":"13","key":"1143_CR44","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681\u201390.","journal-title":"JAMA"},{"issue":"21","key":"1143_CR45","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395.","journal-title":"Circulation"},{"issue":"6","key":"1143_CR46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, B\u00e9gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"1143_CR47","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","volume":"36","author":"AM Mueller","year":"2021","unstructured":"Mueller AM, Liakoni E, Schneider C, Burkard T, Jick SS, Kr\u00e4henb\u00fchl S, et al. The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study. J Gen Intern Med. 2021;36(9):2639\u201347.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"1143_CR48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1615\/IntJMedMushr.v14.i4.30","volume":"14","author":"YC Lo","year":"2012","unstructured":"Lo YC, Lin SY, Ulziijargal E, Chen SY, Chien RC, Tzou YJ, et al. Comparative study of contents of several bioactive components in fruiting bodies and mycelia of culinary-medicinal mushrooms. Int J Med Mushrooms. 2012;14(4):357\u201363.","journal-title":"Int J Med Mushrooms"},{"issue":"6","key":"1143_CR49","first-page":"313","volume":"34","author":"M Klimek","year":"2009","unstructured":"Klimek M, Wang S, Ogunkanmi A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T. 2009;34(6):313\u201327.","journal-title":"P T"},{"issue":"21","key":"1143_CR50","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.1021\/jf071629p","volume":"55","author":"KC Jeng","year":"2007","unstructured":"Jeng KC, Chen CS, Fang YP, Hou RCW, Chen YS. Effect of microbial fermentation on content of statin, GABA, and polyphenols in Pu-Erh tea. J Agric Food Chem. 2007;55(21):8787\u201392.","journal-title":"J Agric Food Chem"},{"issue":"5","key":"1143_CR51","doi-asserted-by":"crossref","first-page":"e248880","DOI":"10.1136\/bcr-2022-248880","volume":"15","author":"B Adler","year":"2022","unstructured":"Adler B, Christopher-Stine L, Tiniakou E. Mushroom supplements triggering a flare of HMGCR immune mediated necrotising myopathy. BMJ Case Rep. 2022;15(5):e248880.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"1143_CR52","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1212\/NXI.0000000000000523","volume":"6","author":"P Mohassel","year":"2018","unstructured":"Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2018;6(1):e523 This study reminds clinicians that children (and possibly some young adults) with suspected muscular dystrophy and very high CK levels should be screened for anti-HMGCR autoantibodies.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"1143_CR53","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/mus.27758","volume":"67","author":"AM Yaworski","year":"2023","unstructured":"Yaworski AM, Blyumin M, Chang T, Mammen AL, Greene M. Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa. Muscle Nerve. 2023;67(2):E1-3.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1143_CR54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11845-021-02651-x","volume":"191","author":"H Wei","year":"2022","unstructured":"Wei H, Xin X, Zhang J, Xie Q, Naveed M, Kaiyan C, et al. Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Ir J Med Sci. 2022;191(2):719\u201325.","journal-title":"Ir J Med Sci"},{"issue":"2","key":"1143_CR55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40256-021-00492-8","volume":"22","author":"Q Hou","year":"2022","unstructured":"Hou Q, Pang C, Chen Y. Association between vitamin D and statin-related myopathy: a meta-analysis. Am J Cardiovasc Drugs. 2022;22(2):183\u201393.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"1143_CR56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","volume":"215","author":"A Gupta","year":"2011","unstructured":"Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1143_CR57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamacardio.2022.4250","volume":"8","author":"MA Hlatky","year":"2023","unstructured":"Hlatky MA, Gonzalez PE, Manson JE, Buring JE, Lee IM, Cook NR, et al. Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo. JAMA Cardiol. 2023;8(1):74\u201380.","journal-title":"JAMA Cardiol"},{"key":"1143_CR58","first-page":"5539595","volume":"2021","author":"M Zabihi","year":"2021","unstructured":"Zabihi M, Askarian F, Hekmatimoghaddam S, Rashidi Nooshabadi M, Zabihi MS, Mousavinasab SR. Ascorbic acid significantly decreases creatine kinase plasma levels in an animal model of statin\/fibrate-induced myopathy. Adv Pharmacol Pharm Sci. 2021;2021:5539595.","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"1143_CR59","unstructured":"Krishna Mohan GV, Chenna VSH, Tirumandyam G, Mian AR, Rashid A, Saleem F. Efficacy and safety of bempedoic acid to prevent cardiovascular events in individuals at risk of cardiovascular diseases: a meta-analysis of randomized-control trials. Cureus. 15(5):e38662"},{"issue":"15","key":"1143_CR60","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"7","key":"1143_CR61","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"1143_CR62","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1143_CR63","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/art.40919","volume":"71","author":"E Tiniakou","year":"2019","unstructured":"Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L. Use of proprotein convertase subtilisin\/kexin type 9 inhibitors in statin-associated immune-mediated necrotizing myopathy: a case series. Arthritis Rheumatol. 2019;71(10):1723\u20136 PCSK9 inhibitors appear to be a safe non-statin alternative treatment for lipid lowering in patients with anti-HMGCR autoantibodies and persistent hypercholesterolemia.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1143_CR64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","volume":"109","author":"BA Parker","year":"2012","unstructured":"Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282\u20137.","journal-title":"Am J Cardiol"},{"issue":"10","key":"1143_CR65","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","volume":"46","author":"PD Thompson","year":"1997","unstructured":"Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206\u201310.","journal-title":"Metabolism"},{"issue":"12","key":"1143_CR66","doi-asserted-by":"crossref","first-page":"e0168065","DOI":"10.1371\/journal.pone.0168065","volume":"11","author":"HR Chung","year":"2016","unstructured":"Chung HR, Vakil M, Munroe M, Parikh A, Meador BM, Wu PT, et al. The impact of exercise on statin-associated skeletal muscle myopathy. PLoS ONE. 2016;11(12):e0168065.","journal-title":"PLoS ONE"},{"issue":"14","key":"1143_CR67","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacc.2023.01.043","volume":"81","author":"NAE Allard","year":"2023","unstructured":"Allard NAE, Janssen L, Lagerwaard B, Nuijten MAH, Bongers CCWG, Rodenburg RJ, et al. Prolonged moderate-intensity exercise does not increase muscle injury markers in symptomatic or asymptomatic statin users. J Am Coll Cardiol. 2023;81(14):1353\u201364.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-024-01143-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-024-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T07:26:46Z","timestamp":1719905206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-024-01143-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s11926-024-01143-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"21 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Christopher-Stine has an intellectual property interest in the anti-HMGCR autoantibody testing and received royalties from Inova Diagnostics\/Werfen for licensing of the anti-HMGCR antibody testing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}